Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
Holding MRNA?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$2.78Last Year’s EPS
$0.55Same Quarter Last Year
Based on 19 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -23.97%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in revenue growth, cost reduction, and pipeline progress. However, challenges remain in RSV sales, international market performance, and competitive pressures in the COVID vaccine market.Company Guidance
During Moderna's Q3 2024 earnings call, the company provided detailed financial guidance and updates on their operational strategy. They reported a revenue of $1.9 billion for the quarter, with a net income of $13 million, and ended with cash and investments totaling $9.2 billion. Moderna highlighted significant cost-saving measures, having reduced operating expenses by $500 million compared to the first quarter of 2024. They maintained their full-year product sales estimate of $3 billion to $3.5 billion, with an anticipated Q4 sales range of $0.8 billion to $1.3 billion. Additionally, Moderna's market share for COVID vaccines in the U.S. retail sector was approximately 40%, and they have been actively working to capture larger market shares in other sectors. The company also discussed its focus on long-term growth through a robust pipeline, aiming for up to 10 product approvals over the next three years, and emphasized ongoing efforts to improve COVID-19 vaccination rates through health care provider education and consumer campaigns.Revenue and Cost Reductions
Moderna delivered $1.9 billion of revenue in Q3 2024. They reduced operating expenses by $500 million compared to Q1 2024, excluding a $1.4 billion resizing charge. Net income improved to $13 million from a loss of $3.6 billion in Q3 2023.
U.S. Market Success
Moderna achieved a 40% share of retail COVID vaccine doses in the U.S. and experienced an earlier launch for the 2024-2025 season that exceeded expectations.
Pipeline Advancements
Moderna reported positive Phase III data for its next-generation COVID vaccine, RSV vaccine, and combination flu-COVID vaccine. Plans to file for approval in 2024 for these products.
Executive Committee Expansion
Moderna expanded its executive committee by promoting internal talent and emphasizing integration of people, culture, and digital innovation.
---
MRNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MRNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $51.81 | $50.28 | -2.95% |
| Aug 01, 2024 | $119.22 | $94.17 | -21.01% |
| May 02, 2024 | $111.46 | $125.59 | +12.68% |
| Feb 22, 2024 | $87.59 | $99.44 | +13.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Moderna (MRNA) report earnings?
Moderna (MRNA) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Moderna (MRNA) earnings time?
Moderna (MRNA) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRNA EPS forecast?
MRNA EPS forecast for the fiscal quarter 2024 (Q4) is -$2.78.
---
